�鶹Ů��

The Supreme Court on Monday rejected the appeal of a Minnesota woman who said she was wrongly denied unemployment benefits after being fired for refusing to be vaccinated for COVID-19 because of her religious beliefs. The Minnesota Department of Employment and Economic Development determined she wasn’t eligible for benefits because her reasons for refusing the vaccine were based less on religion and more on a lack of trust that the vaccine was effective. (Groppe, 4/1)

A new study found that states with a higher percentage of Republican voters are seeing more reports of adverse side effects from COVID-19 vaccines. The study published in the JAMA medical journal looked at 620,456 vaccine adverse events reported to the federal Vaccine Adverse Event Reporting System (VAERS) from adults 18 and older. (Choi, 4/1)

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition. Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital therapeutics company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. (Aguilar, 4/1)

Behind the blockbuster success of drugs like Ozempic and Wegovy is a less-noticed phenomenon: Some people don’t lose much weight on them. There is wide variation in weight loss on these types of drugs, called GLP-1s. Doctors say roughly 10% to 15% of people who try them are “non-responders,” typically defined as those who lose less than 5% of their body weight. These patients, doctors say, don’t experience enough appetite reduction to result in significant weight loss. (Reddy, 4/1)

Costco and its low-cost healthcare partner are expanding into weight-loss management. Costco will begin offering its members in the U.S. access to a weight-loss program through Sesame, a healthcare marketplace, Sesame exclusively told USA TODAY. The service, which will cost $179 every three months, is scheduled to become available April 2. (Lin-Fisher, 4/2)

Only 16% of US adults aged 27 to 45 have received the human papillomavirus (HPV) vaccine, with men, Hispanic respondents, and people with less education at even lower levels, according to a large survey study published last week in Human Vaccines & Immunotherapeutics. Although routine HPV vaccination was initially recommended for children aged 11 to 12 years, with catch-up vaccination through age 26, the Food and Drug Administration (FDA) expanded the age range in 2018 to adults 27 to 45 years, as well. (Wappes, 4/1)